Home Cart 0 Sign in  

[ CAS No. 571188-59-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 571188-59-5
Chemical Structure| 571188-59-5
Structure of 571188-59-5 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 571188-59-5 ]

Related Doc. of [ 571188-59-5 ]

Alternatived Products of [ 571188-59-5 ]

Product Details of [ 571188-59-5 ]

CAS No. :571188-59-5 MDL No. :MFCD11594962
Formula : C14H22N4O2 Boiling Point : -
Linear Structure Formula :- InChI Key :RMULRXHUNOVPEI-UHFFFAOYSA-N
M.W : 278.35 Pubchem ID :11737525
Synonyms :

Calculated chemistry of [ 571188-59-5 ]

Physicochemical Properties

Num. heavy atoms : 20
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.57
Num. rotatable bonds : 4
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 85.84
TPSA : 71.69 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.08 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.41
Log Po/w (XLOGP3) : 1.29
Log Po/w (WLOGP) : 0.97
Log Po/w (MLOGP) : 0.98
Log Po/w (SILICOS-IT) : 0.4
Consensus Log Po/w : 1.21

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.34
Solubility : 1.28 mg/ml ; 0.00461 mol/l
Class : Soluble
Log S (Ali) : -2.4
Solubility : 1.12 mg/ml ; 0.00402 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.35
Solubility : 1.26 mg/ml ; 0.00452 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 0.0
Synthetic accessibility : 2.64

Safety of [ 571188-59-5 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 571188-59-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 571188-59-5 ]
  • Downstream synthetic route of [ 571188-59-5 ]

[ 571188-59-5 ] Synthesis Path-Upstream   1~18

  • 1
  • [ 571189-16-7 ]
  • [ 571188-59-5 ]
YieldReaction ConditionsOperation in experiment
99.1% With palladium 10% on activated carbon; hydrogen In methanol at 25℃; for 4 h; Autoclave Step b): synthesis of 4-(6-Amino-pyridin-3-yl)-piperazine-1-carboxylic acid tert- butyl ester formula 4)Step b): A 10 L autoclave was charged with 328.2 g of nitro 1 -Boc-4-(6-nitro-3- pyridyl)piperazine (formula 3) (1 .064 mol, 1 .00 eq.) and 3.5 L MeOH. The system was purged with N2then 22.7 g of 10percent Pd/C (50percent wet, 21 .3 mmol, 0.02 eq.) were added in one portion. While stirring (300 r.p.m), the reactor was again purged with N2(2 x 2 bar) then pressurized to 3 bar hydrogen. The temperature of the reaction mixture was set to 25°C. IPC of the mixture after 4 h revealed full consumption of starting material. Hydrogen was carefully evacuated from the autoclave and the mixture filtrated. Solids were rinsed with 200 ml MeOH and the filtrate concentrated under reduced pressure. The residue was taken up with 250 ml toluene, concentrated again under reduced pressure and dried at 50°C/15 mbar for 8 h to give 293.5 g of 4-(6-Amino-pyridin-3-yl)- piperazine-1 -carboxylic acid tert-butyl ester (formula 4) as pale violet solid (99.1 percent yield).HPLC (Method 2): 6.65 min (99.6percent) (246 nm).
97% With hydrogen In ethanol at 20℃; for 16 h; Inert atmosphere A 500-mL bottle was purged with nitrogen and charged with 188a (3.1 g, 10 mmol), 10percent palladium on carbon (50percent wet, 1.0 g) and ethanol (100 mL). It was evacuated, charged with hydrogen gas, and stirred for 16 h at room temperature. The hydrogen was then evacuated and nitrogen was charged into the bottle. The catalyst was removed by filtration through a pad of Celite and the filtrate concentrated under reduced pressure to afford 188b (2.7 g, 97percent). MS: [M+H]+ 279
97% With palladium 10% on activated carbon; hydrogen In ethanol at 20℃; for 16 h; A 500-mL bottle was purged with nitrogen and charged with 115a (3.1 g, 10 mmol), 10percent palladium on carbon (50percent wet, 1.0 g) and ethanol (100 mL).
It was evacuated, charged with hydrogen gas, and stirred for 16 h at room temperature.
The hydrogen was then evacuated and nitrogen was charged into the bottle.
The catalyst was removed by filtration through a pad of Celite and the filtrate concentrated under reduced pressure to afford 115b (2.7 g, 97percent). MS: [M+H]+279
97% With palladium 10% on activated carbon; hydrogen In ethanol at 20℃; for 16 h; Example 101h
tert-Butyl 4-(6-Aminopyridin-3-yl)piperazine-1-carboxylate 101h
A 500-mL bottle was purged with nitrogen and charged with tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate 101g (3.1 g, 10 mmol), 10percent palladium on carbon (50percent wet, 1.0 g) and ethanol (100 mL).
It was evacuated, charged with hydrogen gas, and stirred for 16 h at room temperature.
The hydrogen was then evacuated and nitrogen was charged into the bottle.
The catalyst was removed by filtration through a pad of CELITE® and the filtrate concentrated under reduced pressure to afford 101h (2.7 g, 97percent). MS: [M+H]+ 279
97.4%
Stage #1: With iron(III) chloride hexahydrate In ethanol at 80℃; for 0.5 h;
Stage #2: With hydrazine hydrate In ethanol at 80℃; for 14 h;
1-tert-Butoxycarbonyl-4-(6-nitro-3-pyridyl)pyridazine (9.8 g, 31.78 mmol), ferric chloride hexahydrate added in a 250 mL three-neck round bottom flask at room temperature (0.6 g, 2.22 mmol) activated carbon (1.77 g) and ethanol(150mL), heat up to 80 °C for 0.5h, cool down to 65 °C, slowly add hydrazine hydrate (4.5mL, 73.9mmol), continue to heat upThe reaction was stirred at 80 ° C for 14 h, filtered while hot, washed three times with ethanol, most of the ethanol was removed under reduced pressure, and a yellow solid was evaporated.Filtration, drying and recrystallization from ethanol gave yellow acicular solid 1-tert-butoxycarbonyl-4-(6-amino-3-pyridyl)pyridazine8.617 g, yield 97.4percent, purity 98.8percent.
96% With 5%-palladium/activated carbon; hydrogen In ethyl acetate at 42 - 47℃; Inert atmosphere To a vessel was added 4-(6-nitro-pyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester (12.0 g, 1.0 equiv.) along with ethyl acetate (48 mL, 4.0 vol.). To the slurry was added 50percent water wet 5percent Pd/C (480 mg, 4percent w/w) and the vessel was purged three times with nitrogen. The vessel was purged three times with hydrogen and then pressurized to 50 psi hydrogen. The mixture was heated to 42-47°C and allowed to stir until hydrogen uptake ceased (at least 8 hours).The product mixture was filtered and washed with ethyl acetate (2 x 1.5 mL). The combined filtrate was concentrated under reduced pressure to a volume of 6 mL (2 vol.). To the solution was added n-heptane (54 mL, 4.5 vol.) and the mixture was distilled under reduced pressure to a volume of 6 mL (2 vol.). To the solution was added n-heptane (54 mL, 4.5 vol.). The resulting thick slurry was cooled to 20-25°C and allowed to stir for 2 hours. The slurry was filtered and the filter cake washed with n-heptane (36 mL, 3 vol.). The solids were allowed to dry overnight in a vacuum oven at 50-55°C. The 4-(6-amino-pyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester was isolated as a pale orange solid (10.4 g collected; -96percent yield).1H NMR (500 MHz, DMSO-de): δ 7.62 (dd, J = 2.99, 0.60 Hz, 1 H), 7.17 (dd, J = 8.85, 2.99 Hz, 1 H), 6.40 (dd, J = 8.85, 0.60 Hz, 1 H), 5.45 (bs, 2H), 3.43 (m, 2H), 2.85 (m, 2H), 1.41 (s, 9H);13C NMR (125 MHz, DMSO-de): δ 154.8, 153.8, 138.7, 136.8, 125.9, 108.3, 78.9, 50.5, 43.8, 43.0, 28.0; HRMS: Calcd for C14H23N4O2 (M+H)+: 279.18155, Found: 279.18173.
95% With palladium 10% on activated carbon; hydrogen In methanol at 20℃; A suspension of tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate (15.4 g, 50 mmol) in CH3OH (200 mL) with the 1.54 g 10percent palladium carbon was stirred for 5 h at room temperature under an atmosphere of hydrogen gas. The reaction mixture was filtered and concentrated in vacuo to offord 11a (13.2 g, 95.0percent) as a brown solid. MS (ESI) m/z 279.2 [M+H]+; 1H NMR (400MHz, CDCl3): δ 7.77 (d, J=2.50Hz, 1H), 7.17 (dd, J=2.50Hz, 8.90Hz, 1H), 6.49 (d, J=8.80Hz, 1H), 4.20 (s, 2H), 3.57 (t, J=4.80Hz, 4H), 2.96 (t, J=4.90Hz, 4H), 1.48 (s, 9H).
95% With palladium on activated charcoal; hydrogen In methanol; ethanol at 20℃; for 2 h; N,N-Diisopropylethylamine (4.77g, 36.94mmol) was added to a solution of 82 5-bromo-2-nitropyridine (5.00g, 24.63mmol) and 100 tert-butyl piperazine-1-carboxylate (5.10g, 27.09mol) in 101 acetonitrile ([ACN] 30mL). The mixture was refluxed for 2h, cooled to RT, concentrated under a vacuum, and purified by silica gel column chromatography (from 102 PE/86 EA=1:1 to 103 DCM/87 MeOH=20:1) to obtain 104 tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate (3.80g; yield, 50percent) as a yellow solid. Pd/C (100.0mg) was added to a solution of tert-butyl 4-(6-nitropyridin-3-yl) piperazine-1-carboxylate (925.0mg, 3.0mmol) in EA/MeOH (10 mL/10mL). The mixture was degassed by flushing with H2, stirred at RT under a H2 atmosphere for 2h, and filtered and concentrated under a vacuum to obtain INT-3 (792.0mg; yield, 95percent) as an off-white solid. ESI-MS: m/z 279.2 [M+H]+.
95.46% With 5% Pd/C; hydrogen In methanol at 50℃; for 18 h; Step 2
tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate
In a nitrogen atmosphere, to a solution of tert-butyl 4-(6-nitro-3-pyridine) piperazine-1-carboxylate (28.00 g, 90.81 mmol, 1.00 equivalent) in methanol (600 mL) was added palladium on carbon (6percent, 1.7 g).
The suspension was evacuated and filled with hydrogen several times.
The solution was stirred at 50°C in a hydrogen atmosphere (50psi) for 18 hours. TLC (dichloromethane: methanol = 10: 1) showed that the starting material reacted completely.
The suspension was filtered, and the filtrate was dried using a rotary vacuum dryer to give the title compound (24.13 g, 86.69 mmol. 95.46percent yield) as a purple solid. 1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 2.64 Hz, 1H) 7.18 (dd, J = 8.78, 2.89 Hz, 1H) 6.50 (d, J = 8.78 Hz, 1H) 4.21 (brs, 2H) 3.60-3.54 (m, 4H) 3.00-2.92 (m, 4H) 1.48 (s, 9H).
95% With palladium 10% on activated carbon; hydrogen In methanol at 20℃; for 12 h; Add 100 ml of methanol, 0.10 g of 10percent palladium carbon to 100 ml of the reaction vessel, and add 1.8 g of 4-(6-nitropyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester. The system is closed and nitrogen-filled to 0.3. MPa, replacement twice, pass H2 to the reactor pressure 0.3MPa, replace once, then start the reaction at room temperature, reaction 12h, HPLC analysis of the reaction solution, the raw material content is less than 0.5percent. The reaction solution was filtered under reduced pressure through a 0.45 um organic filter, and then evaporated to dryness to give a white solid 1.71 g, product yield 95percent, purity over 99percent.
94% With hydrogen In ethanol; ethyl acetate A mixture of 4-(6-nitro-pyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester (3.40 g, 11.0 mmol) and 10percent Pd-C (400 mg, 0.376 mmol) in ethanol (100 ml) and ethyl acetate (100 ml) is agitated under 1 atmosphere pressure of hydrogen overnight. The mixture is filtered and concentrated to give of 4-(6-amino-pyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester (2.87 g, 94percent yield). MS(ESI) m/z 278 (M+H)+
93% With hydrogen In ethanol; ethyl acetate for 24 h; Step 2. Synthesis of 4-(6-amino-pyridin-3-vD-piperazine-l-carboxylic acid tert- butvl ester; A mixture of 4-(6-nitro-pyridin-3-yl)-piperazine-l-carboxylic acid tert-butyl ester (3.40 g, 11.0 mmol) and 10percent Pd/C (400 mg) in EtOH/EtOAc 1:1 (200ml) was stirred under an atmosphere of hydrogen for 24 hours. The mixture was filtered through glass microfibre filter, reduced in vacuo and dried to afford the title compound as a tan solid (2.87 g, 93percent). (LCMS: Rt 2.41, [M+H]+ 279).
93.4% With hydrogen In methanol; water at 19 - 54℃; for 0.25 h; Inert atmosphere A nitrogen-flushed, 2.5 L heavy-wall Parr bottle (pressure rated to 60 psi) is charged with 68 g (0.22 mol,) of tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate, (A2a), 6.8 g of 10percent palladium on carbon, 50percent water wet catalyst and 807 g (1020 mL) of methanol.
The reaction vessel is inerted three times with nitrogen (ca. 30 psi), evacuating the atmosphere above the reaction mixture each time.
The vessel is pressurized twice with hydrogen (ca. 30 psi), evacuating the atmosphere above the reaction mixture each time.
The reaction vessel is pressurized to 45 psi with hydrogen.
The shaker motor is started.
The reaction is exothermic.
A temperature rise from 19 to 54° C. over 15 min is observed after which time the hydrogen uptake stops.
The mixture is allowed to cool to 30° C. over 1 h at which point the shaker is stopped.
The hydrogen atmosphere is replaced with nitrogen as described above (Inert the reaction vessel).
The catalyst is removed by filtration through a 10 g pad of filter cel.
This entire process is repeated once more, both filtrates are combined and charged to a clean 3 L 4-neck round bottom flask.; The filtrates from Step 2.3 is stirred and concentrated under reduced pressure (50 mbar, 40° C. internal MAXIMUM.) to a thick paste. 190 g (250 mL) of tert-butyl methyl ether is charged to the residue. The sample is again stirred and concentrated under reduced pressure (50 mbar, 30° C. internal MAXIMUM.) to a thick paste. 342 g (500 mL) of heptane is charged to the residue and the resulting suspension is stirred for 15 min at 22+/-3° C. The solids are filtered and the filter cake is washed with 68 g (100 mL) of heptane. Dry the solids at 50° C. for 16 h, to afford 112.3 g (93.4percent) of Compound A2 as tan plates, mp 124-126° C.
93% With palladium 10% on activated carbon; hydrogen In ethanol; ethyl acetate at 20℃; for 12 h; Add to the reaction flask4- (6-nitropyridin-3-yl) piperazine-1-tert-butylcarboxylate (3.4 g, 11 mmol,First step), and palladium on carbon (10percent, 400 mg)Ethyl acetate / ethanol (100 mL, 1: 1).The mixture was stirred at room temperature for 12 hours in a hydrogen atmosphere.Filtered and concentrated under reduced pressure to give the title compound (2.8 g, white solid) in 93percent yield.
93.1% With palladium on activated charcoal; hydrogen In methanol at 20℃; To the reaction flask was added compound 39 (5.65 g, 18.34 mmol)Soluble in methanol,0.5 g Pd / C was added,Catalytic hydrogenation at room temperature,TLC tracking, to be completely complete,Diatomaceous earth, the solvent was removed by distillation under reduced pressure,To obtain a crude solid,And then petroleum ether: ether (30: 1) beating to get pink powder,4.75 g of compound 7-10 was obtained by drying,Yield: 93.1percent.
92% With palladium 10% on activated carbon; hydrogen In ethanol; ethyl acetate at 20℃; A solution of 1-methyl-4-(6-nitro-pyridin-3-yl)-piperazine(45.3 g, 147 mmol) in ethanol (1.4 L) and ethyl acetate(1.4 L) was hydrogenated in the presence of 10percent Pd/C(4.7 g) using an H2 balloon. After 16 h, the reaction mixturewas filtered through a pad of Celite and rinsed withmethanol (2 × 15 mL). The filtrate was concentrated andpurified by column chromatography (1:9 methanol/dichloromethane) to afford the title compound (37.6 g,92percent) as yellow solid. 1H NMR (400MHz, CDCl3): δ 7.75(t, J = 2.7 Hz, 1H), 7.14 (dt, J = 8.6, 3.3 Hz, 1H), 6.47 (dd,J = 8.8, 3.4 Hz, 1H), 4.15 (br s, 2H), 3.54 (t, J = 4.7 Hz Hz,4H), 2.93 (t, J = 4.7 Hz, 4H), 1.45 (s, 9H).
92.03% With palladium 10% on activated carbon; hydrogen In ethanol at 100℃; for 0.00833333 h; 300g of tert-butyl 4-(6-nitro-3-pyridyl)-1-piperazinecarboxylate was weighed into 6LAnhydrous ethanol, stir well and add 20g of 10percent Pd/C,Stir and mix thoroughly to form material I; adjust the flow rate of the slurry pump so that the flow rate of material I is 35.0 g/min, and the flow rate of the H2 gas flowmeter is adjusted to 600 ml/min.The reaction temperature was 100°C, the molar ratio of tert-butyl 4-(6-nitro-3-pyridyl)-1-piperazinecarboxylate to H2 was 1:3.2, and the residence time of the reaction was 27 seconds.The reaction pressure is 1.4Mpa; collect the reaction solution from the reactor outlet,The catalyst was recovered by filtration and the solvent was distilled off under reduced pressure.Add 3 L of ethyl acetate to dissolve, add 15 g of activated carbon, decolorize and stir at room temperature for 1 small test, filter, and add 6 L of cyclohexane to crystallize with stirring.After dropping, cool down to 010°C, heat and stir for 1 small test.The filter cake was rinsed with 300 ml of n-hexane.Evaporation under vacuum at 40°C for 12 hours gave 249.24 g of tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate, yield 92.03percent, purity 99.59percent.
90.88% With palladium 10% on activated carbon; hydrogen In methanol at 20℃; for 4 h; A flask was charged with tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1 -carboxylate (1 g, 4mmol) which was dissolved in methanol (100ml_). The resulting solution was then degassed by evacuation and the vessel back-filled with nitrogen (repeated twice). Palladium, 10 wt. percent on carbon powder, dry (42mg, 0.40mmol) was then added in one portion and the system closed and evacuated again, back-filling with hydrogen (repeated twice). This was left to stir at room temp. After 4 hours, LC-MS showed the reaction was mostly complete, so the system was evacuated and back-filled with nitrogen (repeated twice), the solution filtered through celite and the filtrate concentrated to dryness, affording a brown oily solid tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1 -carboxylate(800mg, 3.63mmol, 90.88percent yield). MS Method 2: RT: 1 .22min, ES+ m/z 279.2 [M+H]+ H NMR (400MHz, CDCb) δ/ppm: 7.70-7.71 (d, J=3.1 Hz, 1 H), 7.08-7.1 1 (d, J=8.0Hz, 1 H), 6.40-6.43 (dd, J=8.0, 3.1 Hz, 1 H), 4.1 1 -4.15 (bs, 2H), 3.50-3.54 (m, 4H), 2.86-2.89 (m, 4H), 1 .42 (s, 9H).
85% With 10% Pd/C; hydrogen In methanol at 20℃; Compound 11c (9.2 g, 29.9 mmol) and wet palladium carbon (2 g) were added into methanol (100 mL), the airin reaction solution was replaced by hydrogen for four to five times, and then the reaction system was stirred underhydrogen atmosphere at room temperature overnight. The reaction solution was filtered, the filter cake was washed witha little methanol, the filtrate was concentrated to give compound 11 (7.1 g, 85percent). LCMS:279M+H)+, RT=1.120min
84% With hydrogen In isopropyl alcohol Example 2: Preparation of 4-(6-Nitro-pyridin-3yl)-piperazine-1-carboxylic acid tert-butyl ester (2); 60.0 g of 20percent Pd(OH)2/C, 1213.1 g (3.9 moles) of intermediate 2a, and isopropanol were charged and stirred in a Parr reactor, then purged under gas, followed by removal of the catalyst under pressure. The filtrates were concentrated in vacuo at -20 0C leaving 917 g of dry brown powder (crude yield -84percent).
83% With hydrogen In methanol; water for 5 h; The tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate synthesized in Reference Example 4 (83 g, 269 mmol) was dissolved in methanol (1.3 L) in Parr Shaker and Raney nickel (15 g, 50percent aqueous suspension) was added thereto. The resultant reaction mixture was stirred under a hydrogen atmosphere (50 psi) for five hours. The reaction mixture was filtered through a Celite pad to separate solid,and the filtrate was concentrated under reduced pressure. The resultant solid was suspended in diethyl ether (120 mL) and stirred for four hours. Heptane was added to the suspension and cooled at 0°C for 45 minutes. The resultant solid was separated by filtration and dried under reduced pressure to yield the title compound (62.5 g, 83percent). ESI-MS (M+H)+ 279, C14H22N4O2=278.17
80% With palladium 10% on activated carbon; hydrogen In ethanol; ethyl acetate at 20℃; for 5 h; Tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1 -carboxylate (41 .3 g, 134 mmol) from example Int01.01 was dissolved in a mixture of ethanol (0.5 L) and ethyl acetate (0.5 L), and 10percent palladium on charcoal (4.10 g) was added. The mixture was stirred at rt for 5 h under hydrogen atmosphere (1 bar). Subsequently, the mixture was filtered and the solvent was removed in vacuo. The residue was triturated with tert-butyl methyl ether and the product collected by suction filtration to yield 26.0 g (69percent) of the title compound. The mother liquor was purified by column chromatography on silica gel (eluent: gradient 100percent ethyl acetate to ethyl acetate / methanol 5: 1 ) to yield further 4.2 g (1 1 percent). 1H-NMR (400MHz, DMSO-d6): δ [ppm]= 1 .41 (s, 9H), 2.83 - 2.87 (m, 4H), 3.40 - 3.44 (m, 4H), 5.45 (s, 2H), 6.39 (d, 1 H), 7.17 (dd, 1 H), 7.61 (d, 1 H).
26 g With ammonium chloride; zinc In methanol at 20℃; for 1 h; Mixture of 5-bromo-2-nitropyridine (40g, 197 mmol, 1.0 eq.), tetrabutylammonium iodide (29.95 g, 216.7 mmol, 1.1 eq.), piperazine (20.06 g, 256.1 mmol, 1.3 eq.) and potassium carbonate (29.95 g, 216.7 mmol 1.1 eq) was dissolved in 450 ml of dimethylsulfoxide. After the reaction was stirred overnight at 80°C, the reaction solution was cooled to room temperature and extracted with dichloromethane and water, the organic phase was washed with a saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated with a rotary evaporator to dryness. The concentrated product after silica gel column chromatography to give yellow solid 4-(6-nitropyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester (48.9 g, crude). The compound obtained above (48.9 g, 197 mmol, 1.0 equiv.) and zinc dust (51.52 g, 788 mmol, 4.0 eq) was dissolved in 1000 ml of methanol was added ammonium chloride (42.15 g, 788 mmol, 4.0 eq.). Stirring at room temperature, after 1 hour, filtered through Celite, and the filtrate was concentrated and extracted with methylene chloride and water, the organic phase was was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated with a rotary evaporator to dryness. The concentrated product by silica gel column chromatography to give a brown solid 4-(6-aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester111 (26.0 g, two -step total yield: 90percent).
7.68 g With hydrogen In methanol at 20℃; for 4 h; 250 mL of reaction flask was added 9. Og (0.029 mol) of intermediate 5 and 150 mL of methanol,Room temperature by adding 0.9g Raney nickel, hydrogen at room temperature after 4h stirring monitoring, raw material reaction completely.Filter, try cake with 20mL methanol wash, the filtrate under reduced pressure spin to dry brown solid 7.68g,HPLC 95percent yield
792 mg With palladium on activated charcoal; hydrogen In methanol; ethyl acetate at 20℃; for 2 h; A reaction flask was charged with 4-(6-nitropyridin-3-yl)piperazine-1-carboxylic acid t-butyl ester (0.92 g, 3.0 mmol) prepared in Step 1, ethyl acetate/methanol (10 mL/10 mL) and Pd/C (0.1 g), and introduced with hydrogen gas.
The reaction was carried out at room temperature for 2 h.
The reaction product was filtered, and concentrated to obtain the titled compound (792 mg, off-white solid).
MS (ESI): mass calcd. for C14H22N4O2 278.2, m/z found 279.2 [M+H]+.

Reference: [1] Bioorganic and Medicinal Chemistry, 2008, vol. 16, # 6, p. 3125 - 3140
[2] Patent: WO2016/30439, 2016, A1, . Location in patent: Page/Page column 30
[3] Patent: WO2011/140488, 2011, A1, . Location in patent: Page/Page column 112; 270
[4] Patent: US2013/116262, 2013, A1, . Location in patent: Paragraph 0315
[5] Patent: EP2773638, 2015, B1, . Location in patent: Paragraph 0170; 0171; 1405
[6] ACS Medicinal Chemistry Letters, 2017, vol. 8, # 6, p. 608 - 613
[7] Patent: CN108822026, 2018, A, . Location in patent: Paragraph 0045-0046; 0049; 0053-0054; 0056; 0060-0061; 0062
[8] Patent: WO2014/128588, 2014, A1, . Location in patent: Page/Page column 33
[9] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 2, p. 348 - 364
[10] European Journal of Medicinal Chemistry, 2018, vol. 144, p. 1 - 28
[11] Patent: EP3269715, 2018, A1, . Location in patent: Paragraph 0123; 0124
[12] Patent: CN108558745, 2018, A, . Location in patent: Paragraph 0030; 0031
[13] Patent: WO2010/20675, 2010, A1, . Location in patent: Page/Page column 50; 51
[14] Patent: WO2008/7123, 2008, A2, . Location in patent: Page/Page column 115
[15] Patent: US2012/115878, 2012, A1, . Location in patent: Page/Page column 9-10
[16] Patent: CN106608879, 2017, A, . Location in patent: Paragraph 0154-0155; 0159-0160
[17] Patent: CN106905245, 2017, A, . Location in patent: Paragraph 0304; 0309; 0310; 0311; 0312
[18] Medicinal Chemistry Research, 2018, vol. 27, # 6, p. 1666 - 1678
[19] Patent: CN107674022, 2018, A, . Location in patent: Paragraph 0034; 0035; 0036; 0037; 0038; 0039-0054
[20] Patent: WO2016/55786, 2016, A1, . Location in patent: Paragraph 00260
[21] Patent: EP2429566, 2016, B1, . Location in patent: Page/Page column 21
[22] Patent: US9808461, 2017, B2, . Location in patent: Page/Page column 22
[23] Patent: EP3284746, 2018, A1, . Location in patent: Paragraph 0096
[24] Patent: WO2008/32157, 2008, A2, . Location in patent: Page/Page column 25
[25] Journal of Medicinal Chemistry, 2005, vol. 48, # 7, p. 2388 - 2406
[26] Journal of Medicinal Chemistry, 2017, vol. 60, # 5, p. 1892 - 1915
[27] Patent: EP3305785, 2018, A1, . Location in patent: Paragraph 0174; 0175
[28] Patent: WO2014/195274, 2014, A1, . Location in patent: Page/Page column 49
[29] Patent: WO2006/95159, 2006, A1, . Location in patent: Page/Page column 78
[30] Patent: WO2006/8545, 2006, A2, . Location in patent: Page/Page column 153
[31] Patent: WO2010/101849, 2010, A1, . Location in patent: Page/Page column 61
[32] Journal of Medicinal Chemistry, 2010, vol. 53, # 22, p. 7938 - 7957
[33] Patent: WO2012/97682, 2012, A1, . Location in patent: Page/Page column 158
[34] European Journal of Medicinal Chemistry, 2014, vol. 81, p. 341 - 349
[35] Patent: WO2015/131080, 2015, A1, . Location in patent: Paragraph 00669; 00671
[36] Patent: CN105622638, 2016, A, . Location in patent: Paragraph 0200
[37] Patent: CN106749259, 2017, A, . Location in patent: Paragraph 0013; 0048; 0111; 0123; 0135
[38] Patent: CN105153149, 2017, B, . Location in patent: Page/Page column 2; 7; 8; 9
[39] Journal of Medicinal Chemistry, 2018, vol. 61, # 6, p. 2227 - 2245
[40] British Journal of Pharmacology, 2018, vol. 175, # 12, p. 2399 - 2413
[41] Journal of Medicinal Chemistry, 2018,
[42] Patent: EP3385262, 2018, A1, . Location in patent: Paragraph 0076; 0077; 0078
  • 2
  • [ 504-29-0 ]
  • [ 57260-71-6 ]
  • [ 571188-59-5 ]
YieldReaction ConditionsOperation in experiment
95% With 2,2,6,6-Tetramethyl-1-piperidinyloxy free radical; oxygen In 1,2-dichloro-ethane for 10 h; Irradiation 2-aminopyridine, piperazine-1-carboxylic acid tert-butyl ester,The acridine salt visible light catalyst, 2,2,6,6-tetramethylpiperidine-nitrogen-oxide is added to anhydrous dichloroethane, and then the reaction environment is replaced with oxygen three times, and irradiated with a blue LED.The reaction time is 10h. After the reaction is completed, the filtrate is spun dry and separated by column chromatography.The title product was obtained as a colorless white solid, yield 95percent.
Reference: [1] Patent: CN108558792, 2018, A, . Location in patent: Paragraph 0025; 0026; 0027; 0034; 0041; 0048; 0055; 0062
  • 3
  • [ 39856-50-3 ]
  • [ 571188-59-5 ]
Reference: [1] Journal of Medicinal Chemistry, 2005, vol. 48, # 7, p. 2388 - 2406
[2] Journal of Medicinal Chemistry, 2010, vol. 53, # 22, p. 7938 - 7957
[3] Patent: WO2011/140488, 2011, A1,
[4] Patent: US2013/116262, 2013, A1,
[5] European Journal of Medicinal Chemistry, 2014, vol. 81, p. 341 - 349
[6] Patent: WO2014/128588, 2014, A1,
[7] Patent: WO2014/195274, 2014, A1,
[8] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 2, p. 348 - 364
[9] Patent: WO2015/131080, 2015, A1,
[10] Patent: EP2773638, 2015, B1,
[11] Patent: WO2016/30439, 2016, A1,
[12] Patent: EP2429566, 2016, B1,
[13] Journal of Medicinal Chemistry, 2017, vol. 60, # 5, p. 1892 - 1915
[14] Patent: CN106608879, 2017, A,
[15] Patent: CN106749259, 2017, A,
[16] ACS Medicinal Chemistry Letters, 2017, vol. 8, # 6, p. 608 - 613
[17] European Journal of Medicinal Chemistry, 2018, vol. 144, p. 1 - 28
[18] Patent: EP3284746, 2018, A1,
[19] Journal of Medicinal Chemistry, 2018, vol. 61, # 6, p. 2227 - 2245
[20] Patent: EP3269715, 2018, A1,
[21] Patent: EP3305785, 2018, A1,
[22] Medicinal Chemistry Research, 2018, vol. 27, # 6, p. 1666 - 1678
[23] British Journal of Pharmacology, 2018, vol. 175, # 12, p. 2399 - 2413
[24] Patent: EP3385262, 2018, A1,
  • 4
  • [ 110-85-0 ]
  • [ 1072-98-6 ]
  • [ 24424-99-5 ]
  • [ 571188-59-5 ]
Reference: [1] Patent: CN108218875, 2018, A, . Location in patent: Paragraph 0044; 0045; 0046; 0047
[2] Patent: CN108210470, 2018, A, . Location in patent: Paragraph 0022; 0023; 0024
[3] Patent: CN108276411, 2018, A, . Location in patent: Paragraph 0018; 0020; 0021; 0022
[4] Patent: CN108250201, 2018, A, . Location in patent: Paragraph 0016; 0018; 0019; 0020
  • 5
  • [ 775288-71-6 ]
  • [ 571188-59-5 ]
Reference: [1] Journal of Medicinal Chemistry, 2005, vol. 48, # 7, p. 2388 - 2406
[2] Journal of Medicinal Chemistry, 2010, vol. 53, # 22, p. 7938 - 7957
[3] Patent: EP3305785, 2018, A1,
[4] British Journal of Pharmacology, 2018, vol. 175, # 12, p. 2399 - 2413
  • 6
  • [ 20511-12-0 ]
  • [ 57260-71-6 ]
  • [ 571188-59-5 ]
Reference: [1] RSC Advances, 2017, vol. 7, # 70, p. 44366 - 44370
  • 7
  • [ 57260-71-6 ]
  • [ 571188-59-5 ]
Reference: [1] Patent: WO2011/140488, 2011, A1,
[2] Patent: US2013/116262, 2013, A1,
[3] European Journal of Medicinal Chemistry, 2014, vol. 81, p. 341 - 349
[4] Patent: WO2014/128588, 2014, A1,
[5] Patent: WO2014/195274, 2014, A1,
[6] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 2, p. 348 - 364
[7] Patent: WO2015/131080, 2015, A1,
[8] Patent: EP2773638, 2015, B1,
[9] Patent: WO2016/30439, 2016, A1,
[10] Patent: WO2016/30439, 2016, A1,
[11] Patent: WO2016/55786, 2016, A1,
[12] Patent: CN106608879, 2017, A,
[13] Patent: CN106749259, 2017, A,
[14] ACS Medicinal Chemistry Letters, 2017, vol. 8, # 6, p. 608 - 613
[15] European Journal of Medicinal Chemistry, 2018, vol. 144, p. 1 - 28
[16] Patent: EP3284746, 2018, A1,
[17] Journal of Medicinal Chemistry, 2018, vol. 61, # 6, p. 2227 - 2245
[18] Medicinal Chemistry Research, 2018, vol. 27, # 6, p. 1666 - 1678
[19] Journal of Medicinal Chemistry, 2018,
[20] Patent: EP3385262, 2018, A1,
  • 8
  • [ 571189-16-7 ]
  • [ 571188-59-5 ]
Reference: [1] Patent: US2003/149001, 2003, A1,
  • 9
  • [ 24424-99-5 ]
  • [ 571188-59-5 ]
Reference: [1] Patent: US2012/115878, 2012, A1,
[2] Patent: EP2429566, 2016, B1,
  • 10
  • [ 779345-37-8 ]
  • [ 571188-59-5 ]
Reference: [1] Patent: WO2012/97682, 2012, A1,
[2] Journal of Medicinal Chemistry, 2018,
  • 11
  • [ 1072-97-5 ]
  • [ 57260-71-6 ]
  • [ 571188-59-5 ]
Reference: [1] RSC Advances, 2017, vol. 7, # 70, p. 44366 - 44370
  • 12
  • [ 21717-96-4 ]
  • [ 571188-59-5 ]
Reference: [1] Patent: WO2012/97682, 2012, A1,
  • 13
  • [ 39856-50-3 ]
  • [ 57260-71-6 ]
  • [ 571188-59-5 ]
Reference: [1] Patent: CN105153149, 2017, B,
[2] Patent: CN106905245, 2017, A,
  • 14
  • [ 52092-47-4 ]
  • [ 571188-59-5 ]
Reference: [1] Patent: WO2016/55786, 2016, A1,
  • 15
  • [ 1072-97-5 ]
  • [ 571188-59-5 ]
Reference: [1] Patent: CN108558745, 2018, A,
  • 16
  • [ 571188-59-5 ]
  • [ 571188-82-4 ]
YieldReaction ConditionsOperation in experiment
99.9%
Stage #1: With isopropyl chloride In tetrahydrofuran at 20℃; for 1 h; Inert atmosphere; Large scale
Stage #2: With isopropylmagnesium chloride In tetrahydrofuran at 70℃; Large scale
10L three bottles into 810g (2.91mol) Compound B, 3.9LTHF, purged with nitrogen and evacuated three times, 20 stirred for 30 minutes and slowly dropping 1.2L isopropyl chloride (2.0Min THF) to the system, 20 incubated for 1 hour, the system was charged with 770g (2.25mol) compounds of the C, vacuum purged with nitrogen three times, and slowly added dropwise isopropylmagnesium chloride 1.2L (2.0MinTHF) to the system, after completion of the dropwise addition, temperature was raised to 70 The reaction was stirred , TLC monitoring of the reaction process. After completion of the reaction was added to the reaction solution and 1.3L of acetic acid 1.3LTHF (THF) mixture, solid precipitated, suction filtered, the filter cake were washed with acetone, water, acetone beating once, 50 blast drying, solid was constant weight 1338g, a pale yellow solid, yield 99.9percent.
93% With isopropylmagnesium chloride In tetrahydrofuran at 20 - 60℃; Inert atmosphere A dry, nitrogen purged reactor was charged with tetrahydrofuran (900 ml_, 15 ml_/g). The batch temperature was set at 20°C and agitation at 250 RPM was started. The reactor was charged with 4-(6-amino-pyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester (63.4g, 0.2278 moles, 1.3 equiv.) and the mixture held at 20°C for 30 min to dissolve the starting material. The reactor was charged with isopropylmagnesium chloride (93.9 g, 0.193 moles, 1 st charge 1.1 eq) (2.0M in THF, 1.1 equiv.) by pump over 30 min. The batch was maintained at 20°C for 40 min. The reactor was charged with 6-bromo-2-chloro-8-cyclopentyl-5-methyl-8/-/-pyrido[2,3- c]pyrimidin-7-one (60.1g, 0.1755 moles, 1 eq.) all at once and rinsed with THF (50 ml_ rinse). An additional charge of isopropylmagnesium chloride (93.9g, 0.193 moles, 1.1 eq - 2nd charge (2.0M in THF, 1.1 equiv.) was added by pump over 30 min. The batch was held at 20°C for 90 min. and then heated from 20°C to 60°C.After reaction, a mixture of THF (2.86 vol) and HOAc (1 equiv.) was used to quench the reaction. The batch was then seeded with 0.5 wt/wtpercent of 4-{6-[6-bromo-8-cyclopentyl-5-methyl-7- oxo-7,8-dihydro-pyrido[2,3-c]pyrimidin-2-ylamino]-pyridin-3-yl}-piperazine-1-carboxylic acid tert- butyl ester and a mixture of THF (1.14 vol) and HOAc (0.4 equiv.) was charged to complete the precipitation. After cooling to 20°C, the batch was filtered, washed with acetone (4 vol), water (6 vol) and acetone (4 vol).The wet cake was dried under vacuum at 65°C to a constant weight to give 4-{6-[6- bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3-c]pyrimidin-2-ylamino]-pyridin-3-yl}- piperazine-1-carboxylic acid te/f-butyl ester in 93percent yield.1H NMR (600 MHz, THF-d8): δ 9.36 (s, 1 H), 8.87 (s, 1 H), 8.22 (d, J = 8.8 Hz, 1 H), 8.04 (d, J = 2.9 Hz, 1 H), 7.39 (dd, J = 8.8, 2.9 Hz, 1 H), 6.10 (m, 1 H), 3.55 (broad, 4H), 3.09 (broad, 4H), 2.60 (s, 3H), 2.30 (m, 2H), 2.09 (m, 2H), 1.85 (m, 2H), 1.66 (m, 2H), 1.46 (s, 9H);13C NMR (150 MHz, THF-d8): δ 159.5, 158.9, 157.7, 156.0, 155.0, 147.2, 144.62, 144.56, 138.0, 126.7, 1 17.6, 114.2, 108.4, 79.9, 55.5, 50.6, 44.7, 29.0, 28.7, 26.9, 18.1 ; HRMS: Calcd for C27H35N703Br1(M+H)+: 584.19797, Found: 584.1981 1.
92% With lithium hexamethyldisilazane In tetrahydrofuran; N,N-dimethyl-formamide at 0 - 25℃; A mixture of B1 (30.62 g, 110 mmol) and N, N-dimethylformamide (170 mL) was added to the three-necked flask and the mixture was stirred Cold to 0 ~ 5 ,Adding lithium hexamethylsilaneTetrahydrofuran solution(1.0 M, 120 mL, 120 mmol)After stirring at a low temperature for 20 to 30 minutes, compound 5 (34.26 g, 100 mmol) was added dropwise, and the mixture was allowed to stand at room temperature 20 to 25C for 6 to 8 hours. Reaction end plus The mixture was extracted with ethyl acetate (170 mL) and extracted three times with the organic phase saturated brine (170 mL), dried over anhydrous sodium sulfate. After concentration, the compound 10 was separated by a dichloromethane ethyl acetate mixed solvent column chromatography. (53.81 g, 92percent)
91.8%
Stage #1: With lithium hexamethyldisilazane In tetrahydrofuran; toluene at 10℃; for 0.166667 h; Inert atmosphere
Stage #2: at 10 - 20℃; for 1.91 h;
Step c): synthesis of 4-[6-(6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro- pyrido[2,3-d]pyrimidin-2-ylamino)-pyridin-3-yl]-piperazine-1-carboxylic acid tert- butyl ester (formula 6) Step c): A 2 L 3-necked RBF was charged with 54.60 g of 4-(6-Amino-pyridin-3-yl)- piperazine-1 -carboxylic acid tert-butyl ester (0.196 mol, 2.1 eq.) and 360 ml toluene. The mixture was cooled to 10°C then 196 ml of LiHMDS solution (1 M in THF, 0.196 mol, 2.1 eq.) was added dropwise, under argon, within 10 min. After stirring for 10 min at Ι Ο ', a slurry of 32.00 g aryl chloride 6-bromo-2-chloro-8-cyclopentyl-5- methyl-8H-pyrido[2,3-d]pyrimidin-7-one in 250 ml toluene was added dropwise within 10 min. After 15 min, the cooling bath was removed, the mixture stirred at RT for 1 .5 h then quenched with 375 ml of sodium hydrogen carbonate saturated aqueous solution. After 1 h, the precipitated solid was collected by filtration, washed with toluene (240 ml), acetone/water 1 /1 (240 ml), acetone (320 ml) then dried at RT/20 mbar for 6 h to give 50.10 g of 4-[6-(6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3- d]pyrimidin-2-ylamino)-pyridin-3-yl]-piperazine-1 -carboxylic acid tert-butyl ester (formula 6) (91 .8percent yield) as yellow solid.HPLC (Method 1 ): 9.06 min (97.2percent) (254 nm).
85% With isopropylmagnesium chloride In tetrahydrofuran at 0 - 30℃; Inert atmosphere Compound A cast material 304g (1.1mol),Compound B (250 g, 0.73 mol)Dry THF solvent 4000mL, N2 protection,Stirring to dissolve, cooling to 0 ~ 10 or so,1120 mL (2.19 mol) of isopropylmagnesium chloride was added dropwise,Slower temperature increase, the control drop temperature 0 ~ 10 ,Dropping the end of stirring 20min, warming to room temperature 25 ~ 30 or so,The reaction was stirred overnight. Point board shows the reaction of raw materials, the reaction liquid cooling,Dropping 4000mL ammonium chloride solution, stirring for 1 hour, filtered,The filter cake was washed twice with 1000mL water, filtered and dried,Filter cake with 1000mL methyl tert-butyl methyl ether beating beating,1000mL acetone washing cake, drying weighed 366g. Yield 85percent.
470 mg
Stage #1: With lithium hexamethyldisilazane In toluene at 0 - 20℃; for 0.5 h;
Stage #2: at 0 - 20℃; for 0.666667 h;
5)Synthesis of Compound 18: 490mg 4-(6-amino-pyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester was added to 15ml of anhydroustoluene. The system was cooled to 0 °C. 1.05eq LiHMDS was added dropwise. Aftercompletion of the dropwise addition, reaction was continued for 30min at roomtemperature. After the completion of the reaction, the system was cooled to 0 °C. A solution of 5ml toluene containing 300mg ofCompound 17 was added dropwise. After the completion of the dropwise addition,the reaction was warmed to room temperature and reacted for 40min. After thecompletion of the reaction, the system was cooled to 0 °C, and saturated NH4Clsolution was added to quench the reaction. After liquid separation, the organicphase was concentrated. Ethyl acetate was added and the system was filtered togive 470mg yellow solid as Compound 18.
44 g
Stage #1: With isopropylmagnesium chloride In tetrahydrofuran at 0 - 20℃; for 1 h; Inert atmosphere
36 g of Compound A was added to 250 ml of tetrahydrofuran,Cool the system to 0 ° C;Under nitrogen protection,A solution of 240 mL of isopropylmagnesium chloride (1 M) in tetrahydrofuran was slowly added dropwise,After dripping,The system was warmed to room temperature and continued to react for 1 h;Then 35 g of compound B was added,Continue to react overnightThe reaction was quenched by the addition of saturated NH4Cl solution,Extracted three times with ethyl acetate,Combined organic phase,Dry, concentrated,To obtain 44 g of the compound represented by the formula (IV)
44 g
Stage #1: With isopropylmagnesium chloride In tetrahydrofuran at 0℃; for 1 h; Inert atmosphere
Stage #2: Inert atmosphere
Take 36g of compound A into 250mL of tetrahydrofuran, the system was cooled to 0 ;Under nitrogen protection,Slowly add 240 mL of isopropylmagnesium chloride (1 M)Tetrahydrofuran solution, after the addition was completed,The system was warmed to room temperature and continued to react for 1 h;Then 35 g of compound B was added,The reaction was continued overnight, and saturated saturated NH4Cl solution was addedThe reaction was quenched, extracted three times with ethyl acetate, the organic phases combined, dried, concentrated,To 44 g of compound DP-1;The procedure for synthesizing the compound of formula DP-1 in this step refers to the preparation method in the patent document (CN 104447739 A).
88 g
Stage #1: With cyclohexylmagnesiumchloride In tetrahydrofuran at 10 - 16℃; Inert atmosphere
Stage #2: With 6-bromo-2-chloro-8-cyclopentyl-5-methylpyridino[2,3-d]pyrimidin-7(8H)-one In tetrahydrofuran at 10 - 16℃; Inert atmosphere
105gm 6-Bromo-2-chloro-8-cyclopentyl-5 -methylpyrido[2,3 -dl pyrimidin-7(8H)-one (Ill) was added in 13 volume of THF, cooled at 10-16°C, followed by addition of 225.0 ml of cyclohexyl magnesium chloride slowly under nitrogen over a period of 60 to 90 minutes,maintaining the temperature of reaction material to 10-1 5°C. The mixture was stirred for3 Ominutes at 10-15°C. Further, 100gm of 4-(6-aminopyridin-3 -yl)piperazine- 1 -carboxylic acid tert-butyl ester (VI) was added lot wise at 10-16°C followed by addition of 225 ml cyclohexyl magnesium chloride at 10-16°C under nitrogen in time interval of 60-90 minutes. The material was stirred for 120 to 180 minutes at 10-16°C and checked for completion ofreaction. On completion of reaction, a mixture of 300 ml of THF and 24 ml of acetic acid was added at 5-15°C. The product thus obtained was stirred for 240 minutes at 25-35°C, cooled to 10±5°C, stirred for 120 minutes at 5-10°C, followed by filtration and washed with S volume of acetone, S volume of hot water (SO-S S°C) and S volume of acetone. The crude material was dried at S0±S°C under vacuum for 8 hours to get 88 gm of 4-[6-(6-Bromo-8-cyclopentyl-S -methyl-7-oxo-7,8-dihydropyrido [2,3 -d]pyrimidin-2-ylamino)-pyridin-3 -yl]piperazine-1-carboxylic acid tert-butyl ester (V).‘H NIVIR (300 MHz, CDC13): ö 8.79 (s, 1H), 8.16-8.19 (d, 1H), 8.03-8.04 (m, 2H), 7.31-7.35 (dd, 1H), 5.92-6.04 (q, 1H), 3.60-3.63 (m, 4H), 3.10-3.14 (m, 4H), 2.61 (s,3H), 1.62-1.76 & 2.03-2.18 (m, 4H), 1.81-1.97 &2.24-2.41 (m, 4H), 1.49 (s, 9H).

Reference: [1] Patent: CN105541832, 2016, A, . Location in patent: Paragraph 0059; 0060; 0061; 0062
[2] Patent: WO2014/128588, 2014, A1, . Location in patent: Page/Page column 36
[3] Patent: CN106565707, 2017, A, . Location in patent: Paragraph 0073; 0074; 0075
[4] Patent: WO2016/30439, 2016, A1, . Location in patent: Page/Page column 33
[5] Organic Process Research and Development, 2016, vol. 20, # 7, p. 1191 - 1202
[6] Patent: CN106220627, 2016, A, . Location in patent: Paragraph 0043; 0050; 0057; 0064; 0070; 0071
[7] Patent: CN104447739, 2016, B, . Location in patent: Paragraph 0141; 0151; 0152
[8] Patent: CN106967064, 2017, A, . Location in patent: Paragraph 0050; 0052
[9] Patent: CN106986871, 2017, A, . Location in patent: Paragraph 0040; 0041; 0043
[10] Patent: WO2018/73574, 2018, A1, . Location in patent: Page/Page column 21; 22
  • 17
  • [ 571188-81-3 ]
  • [ 571188-59-5 ]
  • [ 571188-82-4 ]
YieldReaction ConditionsOperation in experiment
38% for 25 h; Heating / reflux EXAMPLE 1 Preparation of 4-R6- (6-BROMO-8-CVCLOPENTVL-5-METHYL-7-OXO-7, 8-DIHVDRO-PYRIDO [2 3- DPVRIMIDIN-2-VLAMINO)-PVRIDIN-3-VLL-PIPERAZINE-1-CARBOXVLIC acid TERT-BUTYL ester A suspension of 6-BROMO-8-CYCLOPENTYL-2-METHANSULFINYL-5-METHYL-8H-PYRIDO [2,3- OGPYRIMIDIN-7-ONE (10.00 G, 0.027 mol, prepared as in Example 6 of WO 01/707041, which is incorporated herein by reference) and 10. 37 g (0.0373 mol) of 4-(6-amino-pyridin-3-yl)- piperazine-1-carboxylic acid tert-butyl ester in toluene (100 mL) was heated under nitrogen in an oil bath for 7 hours. Thin layer CHROMATOGRAPHY (SIOS, 10 percent MEOH/DCM) INDICATED THE presence of both starting materials. The suspension was heated under reflux for an additional 18 hours. The resulting suspension was cooled to RT and filtered to give 4- [6- (6- BROMO-8-CYCLOPENTYL-5-METHYL-7-OXO-7, 8-DIHYDRO-PYRIDO [2, 3-D] PYRIMIDIN-2-YLAMINO)-PYRIDIN-3- YLJ-PIPERAZINE-1-CARBOXYLIC acid tert-butyl ester (5. 93 G, 38 percent).
38% for 15 h; Heating / reflux Preparation 1
Preparation of 4-[6-(6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino)-pyridin-3-yl]-piperazine-1-carboxylic acid tert-butyl ester
A suspension of 6-bromo-8-cyclopentyl-2-methansulfinyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (10.00 g, 0.027 mol, prepared as in Example 6 of WO 01/707041, which is incorporated herein by reference) and 10.37 g (0.0373 mol) of 4-(6-amino-pyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester in toluene (100 mL) was heated under nitrogen in an oil bath for 7 hours.
Thin layer chromatography (SiO2, 10percent MeOH/DCM) indicated the presence of both starting materials.
The suspension was heated under reflux for an additional 18 hours.
The resulting suspension was cooled to RT and filtered to give 4-[6-(6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino)-pyridin-3-yl]-piperazine-1-carboxylic acid tert-butyl ester (5.93 g, 38percent).
Melting point >250° C. MS (APCI) M++1: calc'd, 584.2, found, 584.2.
26.5% for 21 h; Reflux Mixture of compound 109 (500 mg, 1.35 mmol, 1.0 equiv) and compound 308-16 (524 mg, 1.62 mmol, 1.2 eq.) was dissolved in toluene was heated at reflux for 21 hours with stirring the reaction mixture was cooled and washed with toluene and filtered the yellow solid 4-(6-((6-bromo-8-cyclopentyl- 5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-carboxylic acid tert-butyl ester (209 mg, yield: 26.5percent).
Reference: [1] Journal of Medicinal Chemistry, 2005, vol. 48, # 7, p. 2388 - 2406
[2] Patent: WO2005/5426, 2005, A1, . Location in patent: Page/Page column 21
[3] Patent: US2003/149001, 2003, A1,
[4] Patent: US2005/222163, 2005, A1, . Location in patent: Page/Page column 26
[5] Organic Process Research and Development, 2016, vol. 20, # 7, p. 1191 - 1202
[6] Patent: EP2429566, 2016, B1, . Location in patent: Page/Page column 21
[7] Patent: CN105622638, 2016, A, . Location in patent: Paragraph 0226; 0227
[8] Patent: US9808461, 2017, B2, . Location in patent: Page/Page column 22; 23
  • 18
  • [ 571188-59-5 ]
  • [ 571188-82-4 ]
YieldReaction ConditionsOperation in experiment
38% for 25 h; Heating / reflux Comparative Example 1A: Preparation of 4-[6-(6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro- pyrido[2,3-d]pyrimidin-2-ylamino)-pyridin-3-yl]-piperazine-1 -carboxylic acid tert-butyl ester; A suspension of 6-bromo-8-cyclopentyl-2-methansulfinyl-5-methyl-8/-/-pyrido[2,3-cdpyrimidin-7-one (10.00 g, 0.027 mol, prepared as in Example 6 of WO 01/707041 , which is incorporated herein by reference) and 10.37 g (0.0373 mol) of 4-(6-amino-pyhdin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester in toluene (100 ml.) was heated under nitrogen in an oil bath for 7 hours. Thin layer chromatography (SiO2, 10 percent MeOH/DCM) indicated the presence of both starting materials. The suspension was heated under reflux for an additional 18 hours. The resulting suspension was cooled to RT and filtered to give 4-{6-(6-bromo- 8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino)-pyridin-3-yl]-piperazine-1- carboxylic acid teπf-btyl eiter~(5.93 g", 38 percent). Melting~pointV25ψ°C. MS (APCI) "M+ +"1T calc'd, 584.2, found, 584.2.
Reference: [1] Patent: WO2008/32157, 2008, A2, . Location in patent: Page/Page column 24
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 571188-59-5 ]

Palbociclib Related Intermediates

Chemical Structure| 39856-50-3

[ 39856-50-3 ]

5-Bromo-2-nitropyridine

Chemical Structure| 571188-82-4

[ 571188-82-4 ]

tert-Butyl 4-(6-((6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate

Chemical Structure| 867-13-0

[ 867-13-0 ]

Ethyl 2-(diethoxyphosphoryl)acetate

Chemical Structure| 571189-16-7

[ 571189-16-7 ]

tert-Butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate

Chemical Structure| 866084-31-3

[ 866084-31-3 ]

tert-Butyl 4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate

Ribociclib Intermediates

Chemical Structure| 52092-47-4

[ 52092-47-4 ]

5-Chloro-2-nitropyridine

Chemical Structure| 1374639-77-6

[ 1374639-77-6 ]

(2-Chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methanol

Chemical Structure| 1211443-61-6

[ 1211443-61-6 ]

2-Chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide

Chemical Structure| 571189-16-7

[ 571189-16-7 ]

tert-Butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate

Chemical Structure| 1374639-78-7

[ 1374639-78-7 ]

tert-Butyl 4-(6-((7-cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate

Related Functional Groups of
[ 571188-59-5 ]

Amides

Chemical Structure| 1039055-46-3

[ 1039055-46-3 ]

tert-Butyl (5-aminopyridin-2-yl)(methyl)carbamate

Similarity: 0.84

Chemical Structure| 220731-04-4

[ 220731-04-4 ]

tert-Butyl (5-aminopyridin-2-yl)carbamate

Similarity: 0.80

Chemical Structure| 193902-78-2

[ 193902-78-2 ]

tert-Butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate

Similarity: 0.79

Chemical Structure| 634468-96-5

[ 634468-96-5 ]

tert-Butyl 4-(pyrimidin-5-yl)piperazine-1-carboxylate

Similarity: 0.79

Chemical Structure| 38427-94-0

[ 38427-94-0 ]

tert-Butyl pyridin-2-ylcarbamate

Similarity: 0.75

Amines

Chemical Structure| 1039055-46-3

[ 1039055-46-3 ]

tert-Butyl (5-aminopyridin-2-yl)(methyl)carbamate

Similarity: 0.84

Chemical Structure| 220731-04-4

[ 220731-04-4 ]

tert-Butyl (5-aminopyridin-2-yl)carbamate

Similarity: 0.80

Chemical Structure| 38427-94-0

[ 38427-94-0 ]

tert-Butyl pyridin-2-ylcarbamate

Similarity: 0.75

Chemical Structure| 111669-25-1

[ 111669-25-1 ]

1-Boc-4-(3-Aminopyridin-2-yl)piperazine

Similarity: 0.75

Chemical Structure| 98400-69-2

[ 98400-69-2 ]

4-(Boc-Amino)pyridine

Similarity: 0.73

Related Parent Nucleus of
[ 571188-59-5 ]

Pyridines

Chemical Structure| 1039055-46-3

[ 1039055-46-3 ]

tert-Butyl (5-aminopyridin-2-yl)(methyl)carbamate

Similarity: 0.84

Chemical Structure| 220731-04-4

[ 220731-04-4 ]

tert-Butyl (5-aminopyridin-2-yl)carbamate

Similarity: 0.80

Chemical Structure| 193902-78-2

[ 193902-78-2 ]

tert-Butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate

Similarity: 0.79

Chemical Structure| 38427-94-0

[ 38427-94-0 ]

tert-Butyl pyridin-2-ylcarbamate

Similarity: 0.75

Chemical Structure| 153747-97-8

[ 153747-97-8 ]

tert-Butyl 4-(5-bromopyridin-2-yl)piperazine-1-carboxylate

Similarity: 0.75

Piperazines

Chemical Structure| 193902-78-2

[ 193902-78-2 ]

tert-Butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate

Similarity: 0.79

Chemical Structure| 634468-96-5

[ 634468-96-5 ]

tert-Butyl 4-(pyrimidin-5-yl)piperazine-1-carboxylate

Similarity: 0.79

Chemical Structure| 153747-97-8

[ 153747-97-8 ]

tert-Butyl 4-(5-bromopyridin-2-yl)piperazine-1-carboxylate

Similarity: 0.75

Chemical Structure| 111669-25-1

[ 111669-25-1 ]

1-Boc-4-(3-Aminopyridin-2-yl)piperazine

Similarity: 0.75

Chemical Structure| 170911-92-9

[ 170911-92-9 ]

tert-Butyl 4-(4-aminophenyl)piperazine-1-carboxylate

Similarity: 0.72